EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comorbid depression or anxiety among migraine patients aged ten years or older living in Sweden in 2015 to 2023: A nationwide study

Emily White Johansson iD, Ahmed Nabil Shaaban, Mattias Linde, Anna Ohlis iD, Mathias Mattsson iD, Sofie Gustafsson, Johan Holm iD, Christina Dalman, Emilie E Agardh iD

Cephalalgia · 2026

DOI: 10.1177/03331024261430855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2026. Verfasst von Emily White Johansson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Migraine Disorders, Anxiety, Depression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Sweden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Residential deprivation is a long-established risk factor for poor health outcomes including migraine, depression and anxiety that are significant public health problems in Sweden and globally. Yet the relationship between residential deprivation and patterns of comorbidity among these three conditions is less understood. We aimed to estimate the magnitude and determinants of comorbid depression or anxiety among migraine patients in Sweden including the relationship between residential deprivation and comorbidity prevalence.

Methods

A nationwide register-based cross-sectional study was conducted of persons aged ten years or older in Sweden in 2015–2023. Comorbid depression or anxiety was defined as any depression or anxiety diagnosis or treatment during the migraine-exposed period (from three months before until three months after the first and last recorded migraine exposure in the study period). Small-area deprivation was based on an Index for Multiple Deprivation in Sweden (IMDIS) applied to 5984 small geographic areas. Prevalence ratios (PR) estimated the association between comorbidity and small-area deprivation adjusted for other covariates (age, sex, area of residence, birthplace) using Poisson regression models with robust error variance. We compared sick leave utilization (over fourteen days) for any reason in the migraine-affected years among migraine patients with or without comorbidity.

Results

There were 372,926 migraine patients in the study, and 35.7% (n = 133,219) had comorbid depression or anxiety. There was higher comorbidity prevalence among migraine patients in the most versus the least deprived areas (PR: 1.18, 95% CI: 1.17–1.20). Although the data have limitations, we found that one-third (31.9%) of migraine patients took sick leave (over fourteen days) for any reason during the migraine-exposed years, which rose to 50.9% among migraine patients with comorbid depression or anxiety.

Conclusions

More than one-third of migraine patients had comorbid depression or anxiety with higher prevalence of comorbidity in the most deprived areas. Common comorbid depression or anxiety among migraine patients underscores the need to consider all three conditions in clinical encounters especially for residents of more deprived residential areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAnxietyDepressionHumansSwedenFemaleMaleCross-Sectional StudiesComorbidityMiddle AgedPrevalenceAdultAdolescentYoung AdultChildRegistries

Stichwörter der Autor:innen

Swedenanxietydepressionmigraineresidential deprivation

Autor:innen und Institutionen

  • Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Global Health and Migration Unit, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Regional Migraine Unit, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Centre for Epidemiology and Community Medicine, Region Stockholm, Stockholm, Sweden.
  • Pfizer AB, Stockholm, Sweden.

ORCID-Profile: Emily White Johansson, Anna Ohlis, Mathias Mattsson, Johan Holm, Emilie E Agardh

Förderung

  • Pfizer Sweden

Zitieren

APA

Johansson, E. W., Shaaban, A. N., Linde, M., Ohlis, A., Mattsson, M., Gustafsson, S., Holm, J., Dalman, C., & Agardh, E. E. (2026). Comorbid depression or anxiety among migraine patients aged ten years or older living in Sweden in 2015 to 2023: A nationwide study. Cephalalgia. https://doi.org/10.1177/03331024261430855

Vancouver

Johansson EW, Shaaban AN, Linde M, Ohlis A, Mattsson M, Gustafsson S, et al. Comorbid depression or anxiety among migraine patients aged ten years or older living in Sweden in 2015 to 2023: A nationwide study. Cephalalgia. 2026. doi:10.1177/03331024261430855

BibTeX
@article{Johansson2026,
  author = {Johansson, Emily White and Shaaban, Ahmed Nabil and Linde, Mattias and Ohlis, Anna and Mattsson, Mathias and Gustafsson, Sofie and Holm, Johan and Dalman, Christina and Agardh, Emilie E},
  title = {Comorbid depression or anxiety among migraine patients aged ten years or older living in Sweden in 2015 to 2023: A nationwide study},
  journal = {Cephalalgia},
  year = {2026},
  doi = {10.1177/03331024261430855}
}
Kostenlos starten →